… COX-2 inhibitors with CRT to treat patients with cervical cancer, our results and those from
the RTOG trial suggest that the potential toxicity of COX-2 inhibitors probably offsets any small …

… cancer. Response of microenvironmental biomarkers to C was seen in the majority, suggesting
a role as early markers … Further follow-up is needed to assess the risk of late toxicity. The …

… of cyclooxygenase-2 (COX-2) and CD34 in pretreatment tumor biopsies from patients on the
RTOG C0128 phase II … This study demonstrates the ability to perform quantitative biomarker …

… the role of cyclooxygenase-2 (COX-2) in the development of cervical cancer and potential
… were used as the background for two clinical trials of celecoxib in advanced cervical cancer. …

… In a phase I–II trial of celecoxib 400 mg twice per day for 2 … , 31 patients with locally advanced
cervical cancer were enrolled. … Clinical trials of cyclooxygenase-2 (COX-2) inhibitors for the …

… in immune cells in the tumour microenvironment, leading to loss of … In a cervical cancer
cell line, celecoxib increased … in normal and cancer cells; although these biomarkers and cell …

… phase I/II studies (1, 2) of cervical cancer treated with chemoradiotherapy (CRT) and celecoxib
… in the recent trial using celecoxib (1) compared with their historical data of CRT (6.9%) for …

156 A prospective phase I/II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with
carcinoma of the cervix with biomarker assessment of the tumor micro environment … People …

… tested in a number of phase I/II clinical trials. When given in … Cyclooxygenase 2 (COX2), an
inducible enzyme responsible for … celecoxib has been tested in a number of phase II/III clinical …

224 A prospective phase I/II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with
carcinoma of the cervix with biomarker assessment of the tumour micro environment … People …